International health experts released a new report today in Stockholm titled "Smoke-free, Reduce Harm", which provides compelling evidence that despite similar levels of nicotine consumption, Sweden has significantly lower rates of tobacco-related diseases compared to other European countries.
The report was published during an event by the Global Health Advocacy Organization Smokefree Sweden, detailing nicotine use rates in Sweden and many similar countries, finding that nicotine use is not a factor in tobacco-related diseases. Furthermore, the report further demonstrates that it is the method of consumption that affects consumer health. While using alternative products such as snus does not pose significant risks, smoking is linked to high rates of death and disease.
Despite having a nicotine consumption rate similar to the European average, Sweden has a lung cancer incidence rate 41% lower than other European countries and a tobacco-related death toll less than half of that in European nations. This stark contrast is attributed to the widespread use of smokeless nicotine products such as snus, nicotine pouches, and e-cigarettes.
"The difference between smoking and using smoke-free products is crucial," said Dr. Karl Fagerström, a public health expert and author of the report. "While nicotine is addictive, it does not lead to serious smoking-related diseases. Our research results support shifting the focus from quitting smoking to using less harmful alternatives for those who cannot quit completely."
Sweden has taken proactive measures in public health education and regulatory frameworks to encourage transitioning to these alternative options, with significant impact on public health outcomes. The report highlights that adopting similar harm reduction strategies could be crucial for other countries' efforts to reduce the health impacts of tobacco use.
Dr. Karl added: "The experience in Sweden shows that understanding and addressing misconceptions about nicotine among the public can lead to better consumer protection and informed public health policies."
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
